10x Genomics (NASDAQ:TXG) Downgraded by Leerink Partnrs to “Hold”

Leerink Partnrs cut shares of 10x Genomics (NASDAQ:TXG) from a strong-buy rating to a hold rating in a research note released on Thursday,Zacks.com reports. Leerink Partnrs also issued estimates for 10x Genomics’ Q1 2026 earnings at ($0.35) EPS.

Several other brokerages also recently commented on TXG. Leerink Partners downgraded shares of 10x Genomics from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $25.00 to $12.00 in a research note on Thursday. Citigroup lowered their target price on 10x Genomics from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday. Stifel Nicolaus cut their price target on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday. JPMorgan Chase & Co. decreased their target price on 10x Genomics from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Thursday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of 10x Genomics in a report on Saturday, February 1st. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, 10x Genomics presently has an average rating of “Hold” and an average price target of $20.71.

10x Genomics Stock Performance

10x Genomics stock opened at $11.94 on Thursday. The business’s fifty day moving average is $14.75 and its two-hundred day moving average is $17.43. The firm has a market cap of $1.45 billion, a P/E ratio of -7.80 and a beta of 1.85. 10x Genomics has a 52 week low of $10.80 and a 52 week high of $51.22.

10x Genomics (NASDAQ:TXG) last released its earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 28.93% and a negative return on equity of 25.07%. On average, equities research analysts predict that 10x Genomics will post -1.43 earnings per share for the current year.

Institutional Trading of 10x Genomics

Institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. grew its position in 10x Genomics by 355.0% in the third quarter. JPMorgan Chase & Co. now owns 355,488 shares of the company’s stock valued at $8,027,000 after acquiring an additional 277,355 shares during the last quarter. Lecap Asset Management Ltd. bought a new stake in shares of 10x Genomics during the 3rd quarter valued at approximately $877,000. Geode Capital Management LLC increased its position in 10x Genomics by 2.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,815,710 shares of the company’s stock worth $41,009,000 after purchasing an additional 42,777 shares in the last quarter. SG Americas Securities LLC increased its position in 10x Genomics by 209.8% during the 4th quarter. SG Americas Securities LLC now owns 73,046 shares of the company’s stock worth $1,049,000 after purchasing an additional 49,468 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in 10x Genomics in the 3rd quarter valued at approximately $27,778,000. 84.68% of the stock is currently owned by institutional investors.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.